Transparency and acknowledgements - EFA

Project programme
EFA projects		835269,06
	Atopic Eczema Consensus Europe Abbvie	41.433,33	5%	3,98%
	Atopic Eczema Consensus Europe LeoPharma	41.433,33	5%	3,98%
	Atopic Eczema Consensus Europe Sanofi/Regeneron	41.433,33	5%	3,98%
	Atopic Eczema Deferred Income from 2020	5.000	1%	0,48%
	Breathe Coalition Astra Zeneca	29.920	4%	2,87%
	Breathe Coalition Chiesi	29.920	4%	2,87%
	Breathe Coalition BI	29.920	4%	2,87%
	Breathe Coalition GSK	29.920	4%	2,87%
	Breathe Coalition Roche	29.920	4%	2,87%
	Breathe Coalition Deferred Income from 2020	5.000	1%	0,48%
	Capacity Bulding Astra Zeneca	38.225	5%	3,67%
	Capacity Building Chiesi	25.483,33	3%	2,45%
	Capacity Building Novartis	25.483,33	3%	2,45%
	Capcity Building Deferred income from 2020	5.000	1%	0,48%
	DIGIT Astra Zeneca	76.371,4	9%	7,33%
	DIGIT Chiesi	76.371,5	9%	7,33%
	DIGIT MSD	76.371,5	9%	7,33%
	DIGIT OM Pharma	76.371,5	9%	7,33%
	DIGIT Roche	76.371,5	9%	7,33%
	Digit Deferred Income from 2020	25.000	3%	2,40%
	Interest Group Chiesi	15.106,67	2%	1,45%
	Interest Group GSK	15.106,67	2%	1,45%
	Interest Group Sanofi/Regeneron	15.106,67	2%	1,45%
	Interest Group Deferred Income from 2020	5.000	1%	0,48%
	Deferred income 2021 to EFA Projects 2022	-169.076,37
EU projects		16.830,26
	3TR	4.549,52	27%	0,44%
	CURE	9.234,38	55%	0,89%
	Immuniverse	3.046,36	18%	0,29%